![[D] ifr Proven outcomes1,2,3.pdf](/uploads/r/null/4/4/5/4456cb9191561a63defaf4d64420637408d950decd5f0775a70c5d3216bb8e72/affe8e2a-15bf-4ae1-bf5f-50669a28c27c-_D__ifr_Proven_outcomes1_2_3_142.jpg)
Pièce
Fait partie de UoA 1
103 résultats avec objets numériques
Afficher les résultats avec des objets numériques
![[A] Patent US8838216.pdf](/uploads/r/null/8/5/9/859fbf78c9d4c6d4eddcdfb710208ff169271cbbe8581c0db288ee8c031f5a23/b46f4e9a-07ab-4f93-8584-f6057b5bb983-_A__Patent_US8838216_142.jpg)
Pièce
Fait partie de UoA 1
![[B] CARTO® CONFIDENSE™ Module with Ripple Mapping.pdf](/uploads/r/null/2/3/2/23281df8fa81b420620187409150b683bb945cefb22a56ccad20692541c8ef80/dd5b7edf-5cb6-48fd-8c9d-51f51f933450-_B__CARTO_r__CONFIDENSE_tm__Module_with_Ripple_Mapping_142.jpg)
Pièce
Fait partie de UoA 1
![[G] Case Study Ripple Mapping Dr. Atwater - YouTube.pdf](/uploads/r/null/9/8/4/9844ccf044e1d3b36ffcdfce4865363310d4de64b76d3fc39b94f87a315f35b5/4fd4b237-6192-42e7-971f-b7123f795fe7-_G__Case_Study_Ripple_Mapping_Dr._Atwater_-_YouTube_142.jpg)
Pièce
Fait partie de UoA 1
![[A] EMA approval document for Ivacaftor, 2015.pdf](/uploads/r/null/8/9/6/8969010570da34537eaf78e175287d4a5135f40e254bc792688c197e09de38bb/67df1c03-b7f5-4133-b31b-d679fff38b87-_A__EMA_approval_document_for_Ivacaftor__2015_142.jpg)
Pièce
Fait partie de UoA 1
![[Eiv] UK Health Service Commissioning NHS Wales, 29 November 2019.pdf](/uploads/r/null/a/4/e/a4e14d3dd97ba41ed4fe68bca72e3f806509ade0510180dac06803ba4516968a/3669d6ef-2ea8-4649-bc32-b694596c911c-_Eiv__UK_Health_Service_Commissioning_NHS_Wales__29_November_2019_142.jpg)
Pièce
Fait partie de UoA 1
![[Gii] Health Service Commissioning of TrikaftaKaftrio NHS Wales.pdf](/uploads/r/null/7/4/9/7499a3f3f1f1dcef0858488e8a0fc40f7d3c1974bdd7896bd1e4f552741e1707/10964f43-4c31-4fea-9e46-a0a4fa9b0f1a-_Gii__Health_Service_Commissioning_of_TrikaftaKaftrio_NHS_Wales_142.jpg)
Pièce
Fait partie de UoA 1
![[Giv] Health Service Commissioning of TrikaftaKaftrio NHS Scotland.pdf](/uploads/r/null/0/9/0/09048357648e2b8fc29f11fffb97b91e09a24886e98fbddc0dca4b182f65cd18/a5b03f20-5da0-4b70-87bd-9fc74875f2a2-_Giv__Health_Service_Commissioning_of_TrikaftaKaftrio_NHS_Scotland_142.jpg)
Pièce
Fait partie de UoA 1
![[C] Minutes of the Joint Committee On Vaccination And Immunisation, February 2019 meeting.pdf](/uploads/r/null/9/b/7/9b77357b481cb26b563e393c06fb592040eaee65489130a21d1210252847749c/5a2702d4-eb8e-4b48-b0db-e92c6490c3b1-_C__Minutes_of_the_Joint_Committee_On_Vaccination_And_Immunisation__February_2019_meeting_142.jpg)
![[F] National Advisory Committee on Immunization (NACI) Canada. LAIV Use in Egg Allergic Individuals Advisory Committee Statement.pdf](/uploads/r/null/0/8/6/086ae511e33f399158b3947b2e2c874707ad2bd4193184eb5c2bd9a0dea4576f/d893f21b-38e3-4694-8e4c-1dcace0c3a11-_F__National_Advisory_Committee_on_Immunization__NACI__Canada._LAIV_Use_in_Egg_Allergic_Individuals_Advisory_Committee_Statement_142.jpg)
![[E] NHS England Specialist Commissioning guidance Lung volume reduction by surgery or endobronchial valve for severe emphysema in adults.pdf](/uploads/r/null/6/5/0/65076b7c0849f0c0189a18b39d622f8c5f226e0f2174c0a89619ea0ce428ae39/9fa6c55e-43be-4475-81f1-545d6d18480f-_E__NHS_England_Specialist_Commissioning_guidance_Lung_volume_reduction_by_surgery_or_endobronchial_valve_for_severe_emphysema_in_adults_142.jpg)
![[A] The World Health Organization (2016). Combating Hepatitis B and C to Reach Elimination by 2030.pdf](/uploads/r/null/d/c/d/dcdc14440b46f5b8526bbffad5b736e1f9b53dd3f946af9d97ec155a836e1fc4/cef9cd25-4355-4e2a-8213-f50dc840a3c4-_A__The_World_Health_Organization__2016_._Combating_Hepatitis_B_and_C_to_Reach_Elimination_by_2030_142.jpg)
![[G] The World Health Organization China (2015) Policy Brief The case for investing in hepatitis B and C treatment in China.pdf](/uploads/r/null/e/a/2/ea2061a05d09cd2bfdf4ac684db4682d80008b4bc247f1dd853841a684a03fa8/e266c1a7-8456-445c-af98-47aeec597201-_G__The_World_Health_Organization_China__2015__Policy_Brief_The_case_for_investing_in_hepatitis_B_and_C_treatment_in_China_142.jpg)
![[A] Corticosteroids for COVID-19 (who.int).pdf](/uploads/r/null/8/a/5/8a57953e29db1656a69b65752e86a618a2da0110e4badfa761e53c023b006032/6b7edc8d-e307-4ce3-8400-6f481640718e-_A__Corticosteroids_for_COVID-19__who.int__142.jpg)
Pièce
Fait partie de UoA 1
![[D] NICE COVID-19 prescribing briefing for the use of corticosteroids. .pdf](/uploads/r/null/e/8/7/e8751c317432764b02848ac4f44029c3a771f967ac84387b50f047cfa8fb7beb/8c5c0994-9096-4843-bcd8-3344d6037e47-_D__NICE_COVID-19_prescribing_briefing_for_the_use_of_corticosteroids.__142.jpg)
Pièce
Fait partie de UoA 1
![[A] UK SAGE committee meeting minutes 29th October 2014.pdf](/uploads/r/null/3/e/a/3eab7791bdd0ceb4e1818e3589c6488430d400b745f5c71463849eacfd086c20/f3846e4a-d8fd-4139-870c-e1b3cc964542-_A__UK_SAGE_committee_meeting_minutes_29th_October_2014_142.jpg)
Pièce
Fait partie de UoA 1
![[C] South African HIV Society ART guidelines for adults .pdf](/uploads/r/null/f/9/d/f9d0c9ccba1cef71b267ddb0f69b8fa03aa58e98e7b8ceabe8a71f3a71667ebc/b3ba5934-e574-4c83-9a03-70182e830d35-_C__South_African_HIV_Society_ART_guidelines_for_adults__142.jpg)
Pièce
Fait partie de UoA 1
![[E] WHO Guidelines for the treatment of latent tuberculosis – 2018..pdf](/uploads/r/null/7/4/b/74b3751b0dd67a6c1ec3d4188f4aace19a1453fb09b2aecbcd467a5c8319a04b/a281fca4-bd95-40bf-aa48-8628d0853c54-_E__WHO_Guidelines_for_the_treatment_of_latent_tuberculosis_-_2018._142.jpg)
Pièce
Fait partie de UoA 1
![[G] Guidelines for the Treatment of Latent Tuberculosis Infection Recommendations from the National Tuberculosis Controllers Association and CDC, 2020 Morbidity and Mortality Weekly Report February 14 2020.pdf](/uploads/r/null/4/6/e/46ed66d453821f0ddccadce5494a4e14439887fe2a0f1a6659e92729d89545c6/e42813dc-061f-4c04-89f6-a6dc91eafef5-_G__Guidelines_for_the_Treatment_of_Latent_Tuberculosis_Infection_Recommendations_from_the_National_Tuberculosis_Controllers_Association_and_CDC__2020_Morbidity_and_Mortality_Weekly_Report_February_14_2020_142.jpg)